Now that we have stepped over the threshold into 2020, what has the research community learned that will propel progress and how can we enable changes that can move health and science forward?
Here’s a look a 10 trends and big ideas we are watching as this new decade unfolds:
1. Making patients the priority: Retail, banking, and other consumer-focused industries have placed the consumer in the center.
Developing medication, devices, and products for children is not a matter of “shrinking” down the adult version. Delivering solutions to our littlest patients requires a long-term approach that deliberately centers children in all stages of innovation – from ideation to incubation, from clinical trials to market.
Join Chief Innovation Officer of Children’s National Health System Kolaleh Eskandanian and experts in pediatric medical device innovation for a candid discussion on the challenges and opportunities upon designing innovation with children in mind.
BALTIMORE, United States of America, February 6, 2020/APO Group/ — Hemafuse, a surgical autotransfusion device, will revolutionize blood access across Africa. Hemafuse is designed to salvage and recycle whole blood from cases of internal bleeding. The device can be used in both emergencies and scheduled procedures to recover blood from where it pools inside of a patient, into a blood bag, where it is immediately available to be re-transfused back to that same patient.
Montgomery College’s Workforce Development and Continuing Education (WDCE) Program will offer a program for budding entrepreneurs in Montgomery County to gain start-up business resources and get newly created businesses registered. The program, named LaunchCamp, starts April 7 and is a 12-week sprint for entrepreneurial-minded students to turn their ideas into registered businesses with identified customers.
Funded through the Montgomery College Foundation Innovation Fund, this start-up business accelerator is an easy-to-apply program that requires just a 1-page business plan, called the Lean Canvas.
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
“The Best Networking Event in the MidAtlantic.” This will be our 43rd consecutive Sold Out event over the last 9 years! Over 70% of previous attendees surveyed say that CONNECTpreneur is the “Number One” tech and investor event in the Mid-Atlantic region! This unique event is like none other in the Mid-Atlantic, because of the high quality of our attendees, speakers and presenters. And YES, the networking is unprecedented!
Developing medication, devices, and products for children is not a matter of “shrinking” down the adult version. Delivering solutions to our littlest patients requires a long-term approach that deliberately centers children in all stages of innovation – from ideation to incubation, from clinical trials to market.
Around the world, populations are getting older, and their health needs are becoming more complex. At the same time, technological advances are changing healthcare delivery. In this edition, The Next Normal explores how hospitals will innovate in the coming decade—and what it will mean for both patients and healthcare professionals.
February is Rare Disease Awareness Month, a month-long celebration focused on the suffering and triumphs of patients and their families stricken by rare diseases culminating on February 29th – International Rare Disease Day. The rapidly developing cell and gene therapy fields in recent years have led to a rare disease R&D boom of sorts, with an estimated 800 rare disease-focused clinical development projects currently in process. The biotech industry sees a new window for improving rare disease patient’s lives and potentially curing rare diseases that impact one in ten American and an estimated 400 million people globally.
Image: https://biobuzz.ios
GlaxoSmithKline has licensed a tuberculosis vaccine to the Bill & Melinda Gates Medical Research Institute (MRI). The deal sets the stage for a push to build on recent phase 2b data and make the vaccine available in low-income countries where TB is prevalent.
The vaccine, M72/AS01E, is made up of an immunogenic fusion protein based on two TB antigens. GSK combined that protein with the adjuvant found in its shingles prophylactic Shingrix to create a subunit vaccine. Last year, a phase 2b trial linked the vaccine to 50% protection against progression to active pulmonary tuberculosis for three years in adults infected with the mycobacterium.
Image: Bill Gates (CC BY 2.0/Ben Fisher/GAVI Alliance)
